Plain-English translation of NCT07176182 on ClinicalTrials.gov ↗ · Source last updated · Translation generated ·
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether Aimailang, a citrus flavonoid tablet, can be safely combined with standard chemotherapy (called mFOLFOX) given before surgery for advanced rectal cancer. You would receive either the chemotherapy alone or the chemotherapy plus the citrus supplement for 4–6 cycles before your surgery, and researchers will compare how well each approach works.
Some rectal cancers have a specific protein marker (YWHAB) that might make them respond better to this combined treatment approach. Researchers hope that adding this medication to chemotherapy could help shrink tumors more effectively and improve survival for patients with this type of cancer.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either standard chemotherapy alone or chemotherapy combined with citrus flavonoid tablets. Over 8–12 weeks, you'll receive intravenous infusions of chemotherapy drugs on a schedule (typically every 2 weeks for 4–6 cycles). After completing the treatment, your doctors will assess how well it worked, and you'll undergo surgery to remove the tumor. The study will follow you for at least 3 years to track how long you remain cancer-free and to monitor your overall health.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China